In the second quarter of 2025, HBC reported total operating revenues of NOK 68.4 million, down from NOK 80.4 million in Q2 2024. EBITDA was negative NOK 5.4 million compared to NOK -2.0 million last year. Cash and cash equivalents decreased by NOK 3.9 million, reaching NOK 68.0 million. Total liquidity was NOK 76.5 million on June 30, 2025.

Key highlights for HBC in Q2 2025 include a 180% increase in Human Nutrition B2B Sales, driven by demand in Europe, China, and Southeast Asia. OmeGo® and ProGo® led product launches with strong market positioning. Brilliant Salmon Oil expanded to over 25 countries. CalGo® bone health study showed prevention of bone loss and increased bone mass.

HBC, a Norwegian consumer and pet health company, focuses on sustainability and utilizing natural resources. Their products include ProGo®, OmeGo®, and CalGo® / NT-II® for human and pet health. Scientific evidence supports health benefits, such as improved iron metabolism and immune health. HBC is listed on the Oslo Stock Exchange under ticker “HBC”.

Read more at GlobeNewswire: SECOND QUARTER 2025 FINANCIAL REPORT